Trametinib

Generic Name
Trametinib
Brand Names
Mekinist, Spexotras
Drug Type
Small Molecule
Chemical Formula
C26H23FIN5O4
CAS Number
871700-17-3
Unique Ingredient Identifier
33E86K87QN
Background

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...

Indication

Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

It is used in combination with dabrafenib for the:
...

Associated Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
Associated Therapies
-
Clinical Trials
Related News

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

First Posted Date
2022-12-30
Last Posted Date
2024-07-18
Lead Sponsor
C4 Therapeutics, Inc.
Target Recruit Count
206
Registration Number
NCT05668585
Locations
🇪🇸

NEXT Oncology Barcelona, Barcelona, Spain

🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

🇫🇷

Institut Bergonie, Bordeaux Cedex, France

and more 13 locations

HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies

First Posted Date
2022-12-21
Last Posted Date
2024-11-11
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
26
Registration Number
NCT05658640
Locations
🇦🇹

St. Anna Kinderspital, Vienna, Austria

🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇩🇰

Rigshospitalet Copenhagen, Copenhagen, Denmark

and more 33 locations

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

Phase 1
Completed
Conditions
Rosacea, Erythematotelangiectatic
Interventions
Drug: Trametinib
First Posted Date
2022-11-15
Last Posted Date
2023-05-30
Lead Sponsor
Albany Research Institute, Inc.
Target Recruit Count
12
Registration Number
NCT05616923
Locations
🇺🇸

Samuel S. Stratton VA Medical Center, Albany, New York, United States

PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer

Phase 2
Recruiting
Conditions
Pancreatic Cancer
Interventions
Drug: Trametinib
Drug: Hydroxychloroquine
First Posted Date
2022-08-26
Last Posted Date
2023-06-18
Lead Sponsor
Cancer Trials Ireland
Target Recruit Count
22
Registration Number
NCT05518110
Locations
🇮🇪

Mater Misericordiae University Hospital, Dublin, Ireland

🇮🇪

St Vincent's University Hospital, Dublin, Ireland

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2022-07-01
Last Posted Date
2023-11-28
Lead Sponsor
Peter Hosein, MD
Target Recruit Count
35
Registration Number
NCT05440942
Locations
🇺🇸

University of Miami, Miami, Florida, United States

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

First Posted Date
2022-06-28
Last Posted Date
2024-06-11
Lead Sponsor
Collin Blakely
Target Recruit Count
3
Registration Number
NCT05435846
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

First Posted Date
2022-05-12
Last Posted Date
2024-08-09
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
220
Registration Number
NCT05372354
Locations
🇨🇦

University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario, Canada

🇺🇸

John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 14 locations

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

First Posted Date
2022-05-03
Last Posted Date
2024-11-15
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
346
Registration Number
NCT05358249
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

NYU School of Medicine, New York, New York, United States

and more 1 locations

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Phase 2
Withdrawn
Conditions
Melanoma
Interventions
Drug: dabrafenib
Drug: Trametinib
First Posted Date
2022-03-29
Last Posted Date
2023-09-14
Lead Sponsor
Fondazione Melanoma Onlus
Registration Number
NCT05299580
Locations
🇮🇹

National Institute of Cancer, Bari, Italy

🇮🇹

IRCCS San Martino - IST, Genova, Italy

🇮🇹

Azienda Ospedaliera Universitaria di Modena, Modena, Italy

and more 13 locations

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

First Posted Date
2022-03-11
Last Posted Date
2024-01-23
Lead Sponsor
Xynomic Pharmaceuticals, Inc.
Target Recruit Count
221
Registration Number
NCT05275374
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy